Century Therapeutics Inc (IPSC) - Net Assets
Based on the latest financial reports, Century Therapeutics Inc (IPSC) has net assets worth $158.94 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($223.70 Million) and total liabilities ($64.77 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Century Therapeutics Inc to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $158.94 Million |
| % of Total Assets | 71.05% |
| Annual Growth Rate | -7.84% |
| 5-Year Change | -59.89% |
| 10-Year Change | N/A |
| Growth Volatility | 49.23 |
Century Therapeutics Inc - Net Assets Trend (2015–2025)
This chart illustrates how Century Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See IPSC cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Century Therapeutics Inc (2015–2025)
The table below shows the annual net assets of Century Therapeutics Inc from 2015 to 2025. For live valuation and market cap data, see Century Therapeutics Inc (IPSC) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $158.94 Million | -1.50% |
| 2024-12-31 | $161.36 Million | -12.66% |
| 2023-12-31 | $184.75 Million | -38.97% |
| 2022-12-31 | $302.74 Million | -23.60% |
| 2021-12-31 | $396.24 Million | +472.36% |
| 2020-12-31 | $-106.41 Million | -15.84% |
| 2019-12-31 | $-91.86 Million | -150.35% |
| 2016-12-31 | $182.46 Million | -49.28% |
| 2015-12-31 | $359.71 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Century Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 79191700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.00K | 0.01% |
| Other Comprehensive Income | $30.00K | 0.02% |
| Other Components | $950.81 Million | 598.24% |
| Total Equity | $158.94 Million | 100.00% |
Century Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Century Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Taiwan Paiho Ltd
TW:9938
|
$413.05 Million |
|
SHELF DRILLING LTD
F:6SD
|
$413.20 Million |
|
PEPPER MONEY LTD.
F:X95
|
$413.28 Million |
|
Lindex Group
HE:LINDEX
|
$413.29 Million |
|
Ocugen Inc
NASDAQ:OCGN
|
$413.00 Million |
|
Sansec Technology Co. Ltd. A
SHG:688489
|
$412.87 Million |
|
Samji Electronics Co. Ltd
KQ:037460
|
$412.85 Million |
|
Burstone Group Limited
JSE:BTN
|
$412.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Century Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 161,362,000 to 158,936,000, a change of -2,426,000 (-1.5%).
- Net loss of 9,580,000 reduced equity.
- New share issuances of 173,000 increased equity.
- Other comprehensive income decreased equity by 294,000.
- Other factors increased equity by 7,275,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.58 Million | -6.03% |
| Share Issuances | $173.00K | +0.11% |
| Other Comprehensive Income | $-294.00K | -0.18% |
| Other Changes | $7.28 Million | +4.58% |
| Total Change | $- | -1.50% |
Book Value vs Market Value Analysis
This analysis compares Century Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.25x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-1.68 | $2.29 | x |
| 2020-12-31 | $-1.94 | $2.29 | x |
| 2021-12-31 | $7.20 | $2.29 | x |
| 2022-12-31 | $5.24 | $2.29 | x |
| 2023-12-31 | $3.11 | $2.29 | x |
| 2024-12-31 | $2.05 | $2.29 | x |
| 2025-12-31 | $1.84 | $2.29 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Century Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -6.03%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8.78%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 1.41x
- Recent ROE (-6.03%) is above the historical average (-32.27%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-235.58 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-42.93 Million |
| 2021 | -24.18% | -9057.09% | 0.00x | 1.10x | $-135.45 Million |
| 2022 | -43.25% | -2518.41% | 0.01x | 1.61x | $-161.21 Million |
| 2023 | -73.98% | -6115.12% | 0.01x | 1.95x | $-155.15 Million |
| 2024 | -78.44% | -1920.87% | 0.02x | 2.19x | $-142.70 Million |
| 2025 | -6.03% | -8.78% | 0.49x | 1.41x | $-25.47 Million |
Industry Comparison
This section compares Century Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $27,896,581
- Average return on equity (ROE) among peers: -64.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Century Therapeutics Inc (IPSC) | $158.94 Million | 0.00% | 0.41x | $413.01 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $85.57 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $328.21 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $35.44 Million | -26.32% | 0.18x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.90 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $67.16 Million | -67.08% | 0.33x | $3.66 Billion |
About Century Therapeutics Inc
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the deve… Read more